The experimental drug, called daraxonrasib, does not cure pancreatic cancer, which is one of the deadliest and most difficult-to-treat cancers, but it gives many patients the next best thing: more time.
Dozens of patients in Illinois and across the country have started receiving an experimental pancreatic cancer medication, which has been heralded as a breakthrough.
